• 主题
高级搜索  >
历史搜索 清空历史
首页> 外国专利> method for determining the effectiveness of a beta7 integrin antagonist for the treatment of a gastrointestinal inflammatory disorder, method for predicting a patient's responsiveness, method for determining the dosage of a beta7 integrin antagonist, method for determining the therapeutic regimen of a beta7 integrin antagonist, method for predicting the prognosis of an inflammatory bowel disease, method of elaborating a treatment and method of identifying a lymphocyte population

method for determining the effectiveness of a beta7 integrin antagonist for the treatment of a gastrointestinal inflammatory disorder, method for predicting a patient's responsiveness, method for determining the dosage of a beta7 integrin antagonist, method for determining the therapeutic regimen of a beta7 integrin antagonist, method for predicting the prognosis of an inflammatory bowel disease, method of elaborating a treatment and method of identifying a lymphocyte population

机译：确定β7整合素拮抗剂治疗胃肠炎性疾病的有效性的方法，预测患者反应性的方法，确定β7整合素拮抗剂的剂量的方法，确定β7整合素拮抗剂的治疗方案的方法，方法用于预测炎性肠病的预后，详细的治疗方法和鉴定淋巴细胞群的方法

页面导航
  • 摘要
  • 著录项
  • 相似文献

摘要

method for determining the effectiveness of a beta7 integrin antagonist for the treatment of a gastrointestinal inflammatory disorder, method for predicting a patient's responsiveness, method for determining the dosage of a beta7 integrin antagonist, method for determining the therapeutic regimen of a beta7 integrin antagonist, method for predicting the prognosis of an inflammatory bowel disease, method of elaborating a treatment and method of identifying a lymphocyte population the present invention is directed to methods of using biomarkers to evaluate the treatment of gastrointestinal inflammatory disorders with beta7 antagonists, more specifically, the present invention relates to methods of using the level of intestinal return lymphocytes in peripheral blood, the level of drug occupation in the intestinal return lymphocytes, and / or the level of integrin receptors beta7 in intestinal return lymphocytes as i Indicators (or biomarkers) of the effect, efficacy, safety, prognosis and / or dosage of therapeutic agents, such as beta7 integrin antagonists, for the treatment of gastrointestinal inflammatory disorders.
机译：确定β7整合素拮抗剂治疗胃肠炎性疾病的有效性的方法，预测患者反应的方法，确定β7整合素拮抗剂的剂量的方法，确定β7整合素拮抗剂的治疗方案的方法，方法用于预测炎性肠疾病的预后，精心设计的治疗方法和鉴定淋巴细胞群的方法本发明涉及使用生物标志物评估用β7拮抗剂对胃肠道炎性疾病的治疗的方法，更具体地说，本发明涉及将外周血中肠道回流淋巴细胞的水平，肠道回流淋巴细胞中的药物占用水平和/或肠道回流淋巴细胞中的整合素受体β7的水平用作该作用的指标（或生物标记物）的方法，疗效，安全性，预后和/或用于治疗胃肠道炎症性疾病的治疗剂（例如beta7整联蛋白拮抗剂）的剂量。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号